Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital

References

• Banks P, Chan J, Cleary M, . Mantle cell lymphoma: A proposal for unification of morphologic, immunologic and molecular data. Am J Surg Pathol 1992;16:637–640.
   PubMed Web of Science ®Google Scholar
• Zucca E, Stein H, Coiffier B. European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL). Ann Oncol 1994;5:507–511.
   PubMed Web of Science ®Google Scholar
• Pott C, Hoster E, Delfau-Larue MH, . Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010;115:3215–3223.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Medeiros LJ, Hagemeister FB, . Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003;97:586–591.
   PubMed Web of Science ®Google Scholar
• Decaudin D, Bosq J, Munck JN, . Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 cases. Leuk Lymphoma 1997;26:539–550.
   PubMed Web of Science ®Google Scholar
• Determann O, Hoster E, Ott G, . Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385–2387.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Dahlberg S, Nathwani BN, . A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995;85:1075–1082.
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009;114:1469–1476.
   PubMed Web of Science ®Google Scholar
• Klapper W, Hoster E, Determann O, . Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009;2:103–111.
   PubMedGoogle Scholar
• Leitch HA, Gascoyne RD, Chhanabhai M, . Limited-stage mantle-cell lymphoma. Ann Oncol 2003;14:1555–1561.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Jaffe ES. Lymphoid lesions of the head and neck: a model of lymphocyte homing and lymphomagenesis. Mod Pathol 2002;15: 255–263.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, . A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Weigert O, Hiddemann W. Current treatment standards and future strategies in mantle cell lymphoma. Ann Oncol 2008;19 (Suppl 4):iv41–4.
   Google Scholar
• Gill S, Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 2008;49:398–409.
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, . Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–1992.
   PubMed Web of Science ®Google Scholar
• Herrmann A, Hoster E, Zwingers T, . Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511–518.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, . Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27: 1209–1213.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, . The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010;115:1530–1533.
   PubMed Web of Science ®Google Scholar
• Katzenberger T, Petzoldt C, Holler S, . The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006;107:3407.
   PubMed Web of Science ®Google Scholar
• Tiemann M, Schrader C, Klapper W, . Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005;131:29–38.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, . The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3: 185–197.
   PubMed Web of Science ®Google Scholar
• Argatoff LH, Connors JM, Klasa RJ, . Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067–2078.
   PubMed Web of Science ®Google Scholar
• Hartmann E, Fernandez V, Moreno V, . Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 2008;26: 4966–4972.
   PubMed Web of Science ®Google Scholar
• Kouroukis CT, Belch A, Crump M, . Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:1740–1745.
   PubMed Web of Science ®Google Scholar
• Samaha H, Dumontet C, Ketterer N, . Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998;12: 1281–1287.
   PubMed Web of Science ®Google Scholar
• Weisenburger DD, Vose JM, Greiner TC, . Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000;64:190–196.
   Google Scholar
• LaCasce AS, Vandergrift JL, Rodriguez MA, . Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012; 119:2093–2099.
   PubMed Web of Science ®Google Scholar
• M’Kacher R, Bennaceur A, Farace F, . Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma. Oncogene 2003;22:7905–7912.
   PubMed Web of Science ®Google Scholar
• Rosenbluth BD, Yahalom J. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT). Int J Radiat Oncol Biol Phys 2006;65:1185–1191.
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius JF, Trelle S, . Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706–714.
   PubMed Web of Science ®Google Scholar